JP2021525278A5 - - Google Patents

Info

Publication number
JP2021525278A5
JP2021525278A5 JP2021515306A JP2021515306A JP2021525278A5 JP 2021525278 A5 JP2021525278 A5 JP 2021525278A5 JP 2021515306 A JP2021515306 A JP 2021515306A JP 2021515306 A JP2021515306 A JP 2021515306A JP 2021525278 A5 JP2021525278 A5 JP 2021525278A5
Authority
JP
Japan
Prior art keywords
formula
group
optionally substituted
aryl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021515306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525278A (ja
JP7384903B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/054315 external-priority patent/WO2019224790A2/en
Publication of JP2021525278A publication Critical patent/JP2021525278A/ja
Publication of JP2021525278A5 publication Critical patent/JP2021525278A5/ja
Priority to JP2023191446A priority Critical patent/JP7653092B2/ja
Application granted granted Critical
Publication of JP7384903B2 publication Critical patent/JP7384903B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021515306A 2018-05-24 2019-05-24 フルベストラントのプロドラッグ Active JP7384903B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023191446A JP7653092B2 (ja) 2018-05-24 2023-11-09 フルベストラントのプロドラッグ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201821019542 2018-05-24
IN201821019542 2018-05-24
IN201821047939 2018-12-18
IN201821047939 2018-12-18
PCT/IB2019/054315 WO2019224790A2 (en) 2018-05-24 2019-05-24 Prodrugs of fulvestrant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023191446A Division JP7653092B2 (ja) 2018-05-24 2023-11-09 フルベストラントのプロドラッグ

Publications (3)

Publication Number Publication Date
JP2021525278A JP2021525278A (ja) 2021-09-24
JP2021525278A5 true JP2021525278A5 (cg-RX-API-DMAC7.html) 2022-06-13
JP7384903B2 JP7384903B2 (ja) 2023-11-21

Family

ID=68615936

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021515306A Active JP7384903B2 (ja) 2018-05-24 2019-05-24 フルベストラントのプロドラッグ
JP2023191446A Active JP7653092B2 (ja) 2018-05-24 2023-11-09 フルベストラントのプロドラッグ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023191446A Active JP7653092B2 (ja) 2018-05-24 2023-11-09 フルベストラントのプロドラッグ

Country Status (6)

Country Link
US (1) US20210253626A1 (cg-RX-API-DMAC7.html)
EP (1) EP3801553B1 (cg-RX-API-DMAC7.html)
JP (2) JP7384903B2 (cg-RX-API-DMAC7.html)
AU (1) AU2019274815B2 (cg-RX-API-DMAC7.html)
CA (1) CA3101421C (cg-RX-API-DMAC7.html)
WO (1) WO2019224790A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7384903B2 (ja) * 2018-05-24 2023-11-21 ケーアイ ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー フルベストラントのプロドラッグ
AU2020386864A1 (en) * 2019-11-24 2022-06-16 Kashiv Biosciences, Llc Prodrugs of Fulvestrant
WO2021172359A1 (ja) * 2020-02-25 2021-09-02 大日本住友製薬株式会社 Cdk9阻害剤プロドラッグ及びそれを内封するリポソーム
WO2022034587A1 (en) * 2020-08-10 2022-02-17 Tnik Therapeutics Ltd Traf2- AND Nck-INTERACTING KINASE (TNIK) INHIBITORS AND USES THEREOF
WO2023027032A1 (ja) * 2021-08-23 2023-03-02 住友ファーマ株式会社 自己分解型cdk9阻害剤プロドラッグ及びそれを内封するリポソーム
JP2024538818A (ja) * 2021-10-29 2024-10-23 カシーヴ バイオサイエンシズ,リミテッド・ライアビリティ・カンパニー 乳癌治療用注射可能な医薬組成物
CN117957238A (zh) * 2021-12-06 2024-04-30 江苏亚虹医药科技股份有限公司 氟维司群衍生物及其制备方法和医药用途
CN118871116A (zh) * 2021-12-06 2024-10-29 卡希夫生物科学有限公司 用于治疗癌症的化合物
CN119751533B (zh) * 2025-03-10 2026-01-13 山东大学 一种基于雌甾三烯结构的雌激素受体蛋白靶向降解嵌合体衍生物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Therapy
CN102600073B (zh) * 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
US20160060288A1 (en) * 2013-04-18 2016-03-03 Xi'anlibang Pharmaceutical Technology Co., Ltd. Ester derivatives of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-estra-1,3,5(10)-triene-3,17beta-diol having anticancer activity and preparation method thereof
CN103421069A (zh) * 2013-05-23 2013-12-04 中国海洋大学 氟维司群磷酸酯衍生物及其制备方法和应用
WO2016004166A1 (en) 2014-07-02 2016-01-07 Xavier University Of Louisiana Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group
WO2019050850A1 (en) * 2017-09-05 2019-03-14 Primetime Life Sciences, Llc BIGUANIDINE DERIVATIVES OF THERAPEUTIC AGENTS, AND PREPARATION METHODS AND METHODS OF USING SAME
CN108159055A (zh) * 2018-01-04 2018-06-15 西安力邦医药科技有限责任公司 治疗乳腺癌的长效递药系统、其制备方法及应用
JP7384903B2 (ja) * 2018-05-24 2023-11-21 ケーアイ ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー フルベストラントのプロドラッグ

Similar Documents

Publication Publication Date Title
US11040035B2 (en) 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
JP2024520481A5 (cg-RX-API-DMAC7.html)
RU2357971C2 (ru) Производные фосфонооксихиназолина и их фармацевтическое применение
JP2021011495A5 (cg-RX-API-DMAC7.html)
JP2020532506A5 (cg-RX-API-DMAC7.html)
JP2019518766A5 (cg-RX-API-DMAC7.html)
JP2022541467A (ja) オーロラキナーゼ阻害剤およびその使用
RU2004104625A (ru) Аналоги простагландинов в качестве агонистов рецептора ep4
JP2020515610A5 (cg-RX-API-DMAC7.html)
JP2016537358A5 (cg-RX-API-DMAC7.html)
JP2020502092A5 (cg-RX-API-DMAC7.html)
JP2017537158A5 (cg-RX-API-DMAC7.html)
JP2016515598A (ja) N−フェニル−カルボキサミド誘導体およびb型肝炎を治療するための医薬品としてのその使用
JP2005526723A5 (cg-RX-API-DMAC7.html)
RU2003115490A (ru) Амидные производные в качестве антагонистов nmda рецептора
JP2010516635A5 (cg-RX-API-DMAC7.html)
JP2008505157A5 (cg-RX-API-DMAC7.html)
JP2024516033A5 (cg-RX-API-DMAC7.html)
JP2012518634A5 (cg-RX-API-DMAC7.html)
JP2009537550A5 (cg-RX-API-DMAC7.html)
JP2023503898A5 (cg-RX-API-DMAC7.html)
JP2021535213A5 (cg-RX-API-DMAC7.html)
RU2005140379A (ru) Замещенные циклопропильной группой оксазолидиноновые антибиотики и их производные
JP7112755B2 (ja) Jak酵素阻害剤及びその製造方法と用途
JP2002529465A5 (cg-RX-API-DMAC7.html)